# Versant Venture Management, LLC: Form 13F holdings

An institutional investment manager in San Francisco, CA. SEC CIK 1560009.

- Quarter ended: 2026-06-30
- Filed: 2026-08-12
- Reported value: $162.6m
- Positions: 8 (8 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1560009/000119312526347068/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Monte Rosa Therapeutics, Inc. (GLUE)](/companies/glue.md) | Common Stock | $77.0m | 47.3% | 3,180,780 |  | Unchanged |
| [Century Therapeutics, Inc. (IPSC)](/companies/ipsc.md) | Common Stock | $29.8m | 18.3% | 12,166,109 |  | Unchanged |
| [Jade Biosciences, Inc. (JBIO)](/companies/jbio.md) | Common Stock | $22.0m | 13.6% | 991,783 |  | Reduced −534,037 |
| [Lenz Therapeutics, Inc. (LENZ)](/companies/lenz.md) | Common Stock | $15.1m | 9.3% | 2,656,888 |  | Unchanged |
| [Contineum Therapeutics, Inc. (CTNM)](/companies/ctnm.md) | Common Stock | $8.9m | 5.5% | 542,628 |  | Unchanged |
| CRISPR Therapeutics AG | Common Shares | $8.1m | 5.0% | 148,831 |  | Unchanged |
| Skye Bioscience, Inc. | Common Stock | $1.4m | 0.9% | 2,007,704 |  | Unchanged |
| Tempest Therapeutics, Inc. | Common Stock | $299.4k | 0.2% | 269,772 |  | Unchanged |

Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-347068. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.